EUVIMEDEUVIMED entdecken
EditorialKohortenstudie

Incidence if autoimmune inflammatory rheumatic diseases after COVID ‐19 in South Korea: A nationwide cohort study based on health insurance data

Seung Won Lee, Sunyeup Kim, Hyun Ji Jeon, Hong Ki Min iD

International Journal of Rheumatic Diseases · 2024

DOI: 10.1111/1756-185x.15219 ↗

Kurz gefasst

Editorial in der Zeitschrift International Journal of Rheumatic Diseases, 2024. Verfasst von Seung Won Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea. Hauptthemen laut MEDLINE: COVID-19, Rheumatic Diseases, Autoimmune Diseases. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Many medical issues have arisen in the wake of the coronavirus disease 2019 (COVID-19) pandemic, which was caused by SARS-CoV-2. The risk of thromboembolism increased after SARS-CoV-2 infection, as did the mortality rate.1-3 Moreover, SARS-CoV-2 infection has many sequelae, including immune, nervous, cardiac, respiratory, renal, musculoskeletal, and gastrointestinal abnormalities.4 A recent study from Hong Kong reported that COVID-19 increased the risk of developing autoimmune inflammatory rheumatic diseases (AIRDs) such as rheumatoid arthritis (RA), spondyloarthritis (SpA), and vasculitis5; however, the hazard ratio (HR) for AIRDs such as systemic lupus erythematosus (SLE), primary Sjogren's syndrome (pSS), and systemic sclerosis (SSc) did not increase significantly in those with COVID-19.5 Viral infection, a known environmental trigger, can cause AIRDs through several mechanisms, including molecular mimicry, epitope spreading, and bystander activation6; however, additional clinical data are required to clarify the association between infection by SARS-CoV-2 and the occurrence of AIRDs. Here, we used Korean National Health Insurance Service (NHIS) data to compare the incidence of AIRDs between those with a diagnosis of COVID-19 and those without. Reimbursement claims data were obtained from the Korean NHIS database; the NHIS covers 97.2% of the Korean population. The National Health Information Database collects NHIS data, including all healthcare-related information such as health screening, socioeconomic and demographic variables, mortality data, diagnoses, and associated procedures and prescriptions, all of which are identified using the International Classification of Diseases, Tenth Revision (ICD-10) codes, as well as Korean Drug and Anatomical Therapeutic Chemical Codes for the entire population.7 Data from patients who were tested for COVID-19 by RT-PCR (nasal or pharyngeal swabs) from January 2020 to December 2021 were extracted from the NHIS database (approval no. NHIS-2023-1-479) and then divided into COVID-19 PCR (+) and (−) groups. Participants who had ICD-10 codes for AIRDs prior to the COVID-19 PCR assay, or lacked demographic data, were excluded. The index date was the day on which the COVID-19 PCR test was performed, and the end of the follow-up was dated as follows: (1) March 31, 2022, (2) the date on which the first ICD-10 code for AIRDs was issued, or (3) the expired date. In the case of multiple AIRDs codes, the first AIRD code date was taken as the end of follow-up. When individual subjects had undergone multiple COVID-19 PCR assays, the first COVID-19 PCR assay date was used as the index date for the COVID-19 PCR (−) group, and the date of the positive COVID-19 PCR test was used for the COVID-19 PCR (+) group. When the participant was negative for COVID-19 PCR initially and then converted to positive in the latter COVID-19 PCR test, this participant was included in the COVID-19 PCR (+) group, and the index date was when COVID-19 PCR was converted to positive. The study was conducted in accordance with the Declaration of Helsinki and its amendments. The requirement for written informed consent was waived by the Institutional Review Board of Konkuk University Medical Center due to the characteristics of the NHIS data. The study was approved by the Institutional Review Board of the Konkuk University Medical Center (approval number: KUMC 2023-02-018). AIRDs was defined as RA (ICD-10 code: M05, M06.0/2/3/8/9), AS (ICD-10 code: M45), psoriatic arthritis (ICD-10 code: L40.5, M07.0/1/2/3), polymyalgia rheumatica (ICD-10 code: M35.3), SLE (ICD-10 code: M32), primary Sjogren's syndrome (pSS, ICD-10 code: M35.0), systemic sclerosis (SSc, ICD-10 code: M34.0/1/8/9), mixed connective tissue disease (ICD-10 code: M35.1), dermatomyositis/polymyositis (DM/PM, ICD-10 code: M33), polyarteritis nodosa (ICD-10 code: M30.0), Behçet's disease (M35.2), antineutrophil cytoplasmic antibody associated vasculitis (ICD-10 code: M30.1, M31.3, M31.7), giant cell arteritis (ICD-10 code: M31.5, M31.6), or Takayasu's arteritis (M31.4). Occurrence of AIRDs was defined when identical ICD-10 codes for AIRDs were coded at least twice in the same patient. Categorical variables were compared using the Chi-square test, and data were presented as numbers and percentages. The incidence rate (IR) of AIRD is expressed as events per 100 000 person-years (PYs). Data were assessed using two-tailed t-tests and a p-value 60 years in the PCR (+) group was 6241 (62.95%), whereas that in the PCR (−) group was 284 470 (59.13%). Males accounted for 46.66% of the PCR (+) group and 50.27% of the PCR (−) group. Comorbidities, such as diabetes mellitus, cardiovascular disease, cerebrovascular disease, chronic obstructive pulmonary disease, hypertension, and chronic kidney disease were more common in the PCR (+) group than in the PCR (−) group; the most common comorbidity in both groups was hypertension. Current smokers were more prevalent in the PCR (−) group, whereas alcohol consumption and degree of aerobic activity were similar between the two groups. The baseline characteristics of the patients are presented in Table 1. The IR of AIRDs in the PCR (+) group was 107.25 per 100 000 PYs, and that in the PCR (−) group was 440.75 per 100 000 PYs; thus, the IR of AIRDs was significantly lower in the (+) group (p = .008). Three cases of AIRDs (two of RA and one of AS) occurred in the (+) group, whereas 756 cases (410 of RA, 69 of AS, nine of psoriatic arthritis, 28 of polymyalgia rheumatica, 93 of SLE, 47 of primary Sjogren's syndrome, six of SSc, one of mixed connective tissue disease, 19 of dermatomyositis/polymyositis, one of polyarteritis nodosa, 27 of Behçet's disease, 33 of ANCA-associated vasculitis, three of giant cell arteritis, and 10 of Takayasu's arteritis) occurred in the (−) group (Figure 2). The present study used Korean NHIS data deposited prior to the emergence of the Omicron variant of SARS-CoV-2. These data were used to examine the incidence of AIRDs in individuals with COVID-19. Statistical analyses revealed that the IR of AIRDS in the COVID-19 (+) group was not higher than that in the (−) group. Even though the COVID-19 outbreak reached pandemic status very quickly, the underlying immunological mechanisms and sequelae are still not fully understood. Persistent symptoms related to SARS-CoV-2 infection are referred to as "long-COVID syndrome"; 71.2% of COVID-19 infected patients in Korea suffered from long-COVID-19 syndrome.8 Most symptoms of long-COVID-19 syndrome are debilitating but not fatal8; however, some sequelae can be serious and require medical care. COVID-19 affects both the innate and adaptive immune systems; indeed, virus-triggered hyperactivation of helper T cells and antigen-presenting cells causes dysfunction of various organs and systems.4, 6, 9 SARS-CoV2 mutates quickly, resulting in the rapid emergence of variants, each of which may interact with the immune system in different ways.10 A study in Hong Kong showed that the risk of pernicious anemia, SpA, RA, other autoimmune arthritis, psoriasis, pemphigoid, Graves' disease, anti-phospholipid antibody syndrome, immune-mediated thrombocytopenia, multiple sclerosis, and vasculitis was significantly higher in patients with COVID-19 than in those without.5 The risk of other autoimmune diseases, such as DM/PM, pSS, SSc, and SLE was not higher in the COVID-19 group.5 In addition, German routine healthcare data showed a higher incidence rate ratio (IRR) of autoimmune diseases in COVID-19 (+) group than COVID-19 (−) group (IRR = 1.43 with 95% confidence interval 1.37–1.48).11 This study included not only AIRD but also non-rheumatic autoimmune diseases such as Hashimoto thyroiditis, type I diabetes mellitus, ulcerative colitis, Crohn's disease as outcome.11 In the present study, some baseline characteristics, including age, sex, comorbidities, and BMI, differed between the COVID-19 (+) and (−) groups. As a previous study used propensity score (PS) matching with a 1:3 ratio,11 we could not conduct PS matching due to the relatively lower IR of AIRD. Another study based on Columbian health insurance data demonstrated that the HR for RA was significantly higher (HR = 2.01, 95% confidence interval 1.59–2.53) in individuals with COVID-19.12 Although the type of AIRDs differed from those in previous studies,5, 11, 12 the incidence of AIRDs in the present study was not higher. However, the follow-up period in the present study was shorter than that in the previous studies. We used the Korean NHIS data from January 2020 to December 2021, which was collected prior to the emergence of the Omicron variant of SARS-CoV-2, whereas the two previous studies collected data between April 2020 and November 2022,5 or January 2018 to December 2022.12 The short follow-up duration, coupled with the exclusion of the Omicron variant-predominant period, may explain the difference between our results and those of the previous studies.5, 12 In addition, the diagnostic accuracy of the AIRD based on the ICD-10 code of claim data usually differs from the actual diagnosis made by a rheumatologist. The positive predictive value of RA based on ICD-10 code was 55.7–88.9%, and 71.8–88.6% for AS.13, 14 In addition, differences in the medical system, race, and vaccination status of each country may also influence the opposite results between the present study and previous studies.5, 11, 12 Ahn et al. showed that the incidence of rheumatic diseases, specifically inflammatory myositis (DM/PM), SLE, and Behçet's disease, decreased during the COVID-19 pandemic15; the proposed reasons for this were the reduction in healthcare utilization and implementation of non-pharmacological interventions such as mask-wearing.15 The present study has several limitations. First, insurance claims data have intrinsic limitations, and the accuracy of the diagnoses cannot be assessed. The incidence of AIRD was determined using ICD-10 codes, and this method has an intrinsic limitation in diagnostic accuracy. Second, we included SARS-CoV-2 infection data from the Korean NHIS prior to the Omicron variant-predominant period because the NHIS data collected after December 2021 had not been released at the time. This limitation can be overcome by the inclusion of a longer follow-up period in future studies (this is possible due to the prospective nature of Korean NHIS data). Third, missing data on the COVID-19 (+) group may have existed because some people might have omitted the COVID-19 PCR test even if they had suspected COVID-19 symptoms. The COVID-19 PCT test was free in Korea until August 2023; therefore, we assumed that this portion of citizens would be scarce. In conclusion, the data presented herein suggest that the incidence of AIRDs in Korean patients with COVID-19 during the first 2 years of the COVID-19 pandemic was not higher than that in those who did not have COVID-19. All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. H.K. Min had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study conception and design. S.W. Lee, H.K. Min. Acquisition of data. S. Kim, H.J. Jeon. Analysis and interpretation of data. S.W. Lee, H.K. Min, S. Kim, H.J. Jeon. None. None. The authors declare no competing interests. Data are available on reasonable request.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Rheumatic DiseasesAutoimmune DiseasesHumansRepublic of KoreaIncidenceFemaleMaleMiddle AgedAdultSARS-CoV-2Insurance, HealthAgedCohort Studies

Autor:innen und Institutionen

  • Department of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
  • Department of Medical AI, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
  • Department of Metabiohealth, Sungkyunkwan University, Suwon, Republic of Korea.
  • Division of Rheumatology, Department of Internal Medicine, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Hong Ki Min

Zitieren

APA

Lee, S. W., Kim, S., Jeon, H. J., & Min, H. K. (2024). Incidence if autoimmune inflammatory rheumatic diseases after COVID ‐19 in South Korea: A nationwide cohort study based on health insurance data. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.15219

Vancouver

Lee SW, Kim S, Jeon HJ, Min HK. Incidence if autoimmune inflammatory rheumatic diseases after COVID ‐19 in South Korea: A nationwide cohort study based on health insurance data. International Journal of Rheumatic Diseases. 2024. doi:10.1111/1756-185x.15219

BibTeX
@article{Lee2024,
  author = {Lee, Seung Won and Kim, Sunyeup and Jeon, Hyun Ji and Min, Hong Ki},
  title = {Incidence if autoimmune inflammatory rheumatic diseases after COVID ‐19 in South Korea: A nationwide cohort study based on health insurance data},
  journal = {International Journal of Rheumatic Diseases},
  year = {2024},
  doi = {10.1111/1756-185x.15219}
}
Kostenlos starten →